Zai Lab Limited (ZLAB)
30.98
0.01 (0.03%)
At close: Feb 20, 2025, 3:59 PM
30.70
-0.89%
After-hours: Feb 20, 2025, 04:25 PM EST
undefined% (undefined)
| Bid | 30.62 |
| Market Cap | 3.37B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.8 |
| PE Ratio (ttm) | -11.06 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 33 |
| Volume | 674,566 |
| Avg. Volume (20D) | 699,949 |
| Open | 31.16 |
| Previous Close | 30.97 |
| Day's Range | 30.72 - 31.54 |
| 52-Week Range | 13.48 - 36.60 |
| Beta | undefined |
About ZLAB
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and ...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 2,175
Stock Exchange NASDAQ
Ticker Symbol ZLAB
Website https://www.zailaboratory.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ZLAB stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 77.56% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Zai Lab Limited is scheduled to release its earnings on Feb 27, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+1.46%
Zai Lab shares are trading higher. The company pri...
Unlock content with
Pro Subscription
3 months ago
-10.95%
Zai Labs shares are trading lower after the company announced a $200 million proposed public offering.
